Publication: Skin gene therapy for acquired and inherited disorders
Loading...
Identifiers
Publication date
2006-11
Defense date
Advisors
Tutors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad de Murcia
Impact
Export
Abstract
The rapid advances associated with the Human Genome Project combined with the development of proteomics technology set the bases to face the challenge of human gene therapy. Different strategies must be evaluated based on the genetic defect to be corrected. Therefore, the re-expression of the normal counterpart should be sufficient to reverse phenotype in single-gene inherited disorders. A growing number of candidate diseases are being evaluated since the ADA deficiency was selected for the first approved human gene therapy trial (Blaese et al., 1995). To cite some of them: sickle cell anemia, hemophilia, inherited immune deficiencies, hyper-cholesterolemia and cystic fibrosis. The approach does not seem to be so straightforward when a polygenic disorder is going to be treated. Many human traits like diabetes, hypertension, inflammatory diseases and cancer, appear to be due to the combined action of several genes and environment. For instance, several wizard gene therapy strategies have recently been proposed for cancer treatment, including the stimulation of the immune system of the patient (Xue et al., 2005), the targeting of particular signalling pathways to selectively kill cancer cells (Westphal and Melchner, 2002) and the modulation of the interactions with the stroma and the vasculature (Liotta, 2001; Liotta and Kohn, 2001).
Description
Keywords
Skin, Gene therapy, Tissue engineeering
Bibliographic citation
Carretero, M., Escámez, M.J., Prada, F., Mirones, I., García, M., Holguín, A., Duarte, B., Podhajcer, O., Jorcano, J. L., Larcher, F. & Del Río, M. (2006). Skin gene therapy for acquired and inherited disorders. Histology and Histopathology, 21(11), 1233-1247.